HippoFi’s wholly owned subsidiary, PUR Biologics breaks into the worldwide market
IRVINE, CA., December 11, 2023 / OrthoSpineNews / – HippoFi’s (OTCPK: ORHB) biotechnology enterprise PUR Biologics, started promoting and transport merchandise for worldwide use, closing out an exceptional yr of accomplishments.
“These orders are a results of exhausting work and dedication from our valued distribution community consisting of 250 distributors and over 300 gross sales representatives. The expansion and accomplishments of PUR Biologics during the last 12 months are effectively past our expectations. Combining our staff of enterprise and scientific consultants, world companions, and best-in-class applied sciences, with our world-class distribution community has established PUR because the ‘Authority in Spinal Biologics’ and can drive vital gross sales within the yr forward.” shared, CJ Wiggins, Government Chairman and CEO of HippoFi.
The marketplace for spine surgical procedures using organic implants is estimated to be value $3.5 billion, with 1.62 million surgical procedures carried out annually.
Wiggins continued stating, “Our enterprise is primed for robust gross sales progress in 2024 and anticipated to trace over $20 million. We see vital upside for HippoFi and its Shareholders because the market continues to embrace our applied sciences and options geared toward serving to sufferers heal sooner and luxuriate in the next high quality of life following their surgical process.”
In closing Wiggins highlighted, “Our newest acquisition of the activeOrb™ expertise from ZIMMER BIOMET positions us to take an excellent bigger share of the $3.5 billion alternative associated to bone-growth options.”
About PUR Biologics
PUR Biologics, an entirely owned subsidiary of HippoFi, Inc. (OTCPK: ORHB), is a number one biologic firm dedicated to supporting surgeons and hospitals in offering the very best care for his or her sufferers. PUR Biologics’ full line of biologic merchandise presently embrace: superior allografts and demineralized extracellular matrixes (d-ECM), progressive artificial options, mobile derived tissues, and a way forward for subsequent technology regenerative stem cell and progress issue pushed therapeutics for treating osteoarthritis and cartilage regeneration.
About HippoFi, Inc.
HippoFi is a healthcare innovator and publicly traded firm, delivering proprietary applied sciences within the multi-billion-dollar Backbone, Orthopedic, and Most cancers markets. The corporate’s objective is to enhance affected person care and outcomes by using biotech and AI applied sciences to deal with degenerative and diseased situations affecting the standard of life.
HippoFi’s enterprise is designed to drive firm worth by commercializing and monetizing progressive options, buying belongings, and licensing applied sciences, establishing strategic partnerships and trade alliances, and leveraging its worldwide gross sales channels. The operations of the corporate comprise of two segments: Regenerative Therapeutics and Clever Automation.
HippoFi’s Regenerative Therapeutics division is actively creating and deploying scalable organic options into the $1.37 Trillion (13.96% CAGR) biotechnology market by its wholly-owned subsidiary – PUR Biologics.
Capitalizing on HippoFi’s established partnerships with ZIMMER / BIOMET, Hoag Hospital Newport Seaside, BPB Medica, Precision Backbone, and others, PUR Biologics’ staff of trade consultants, pioneering scientists, and world-class medical professionals are using the corporate’s highly effective patent portfolio and proprietary applied sciences to commercialize superior applied sciences that enhance bone progress in spinal fusion procedures, regenerate joint cartilage and intervertebral disc, remove ache and irritation related to osteoarthritis, joints, and the decrease again, and ship a cell-based immunotherapy to assist defeat most cancers.
HippoFi, Inc. is publicly traded beneath the image: ORHB and is headquartered in Irvine, California. For extra info, please go to www.HippoFi.co and www.PURbiologics.com.